Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Epigenomics AG. (7/12/17). "Press Release: Epigenomics AG – Voluntary Public Takeover Offer by Summit Hero Holding Not Successful". Berlin.

Organisations Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
  Organisation 2 Summit Hero Holding GmbH
  Group Cathay Fortune International Co. Ltd. (CFIC)
Products Product Epi proColon® blood test
  Product 2 investment banking
Index term Index term Epigenomics–SEVERAL: investment, 201704–201707 public cash takeover offer €7.52/share FAILED valuing ECX at €171m incl net cash by CFUC + Biochain
Persons Person Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
  Person 2 Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Greg Hamilton, CEO of Epigenomics, commented: „It is unfortunate that the takeover offer has not been successful. We now will carefully explore alternative financing options for Epigenomics in order to successfully commercialize our products and develop innovative cancer tests.”


Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail:

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, please visit

Record changed: 2017-07-20


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

More documents for Epigenomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [MSC] – The Mass Spectrometry Web Portal 600x80px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Picture [LSE] – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px